Articles tagged with Bone Cancer
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
Researchers found that EWS::FLI1 induces Slit2 expression, which activates Robo receptors and enhances Ewing sarcoma growth. Silencing Slit2 strongly inhibited Ewing sarcoma cell growth, providing an opportunity for targeted therapy.
Researchers have identified two subgroups of Ewing sarcoma that respond differently to targeted drug therapy, with the first group responding to Linsitinib and AZD1775 treatment. The study suggests that repeated biopsies may be needed over time to determine the best course of treatment for each patient.
Researchers at UVA Cancer Center have identified interleukin-1 as a crucial contributor to the development of myelofibrosis, a potentially deadly bone marrow cancer. Targeting this cytokine could prevent myelofibrosis from progressing and spare bone marrow scarring.
Researchers at the University of Missouri have successfully used click chemistry to deliver radiopharmaceuticals specifically to tumors in large dogs with bone cancer, increasing effectiveness and minimizing circulation. This breakthrough could pave the way for click chemistry-based treatments for humans with cancer in the future.
UCF researchers have designed a cerium oxide nanoparticle to protect bones against radiation damage from cancer therapy. The treatment also improves bone regeneration and kills cancer cells, reducing the risk of bone fractures and tissue damage.
A new study found that adult survivors of childhood cancer are 80% more likely to be undertreated for cardiovascular risk factors, including hypertension, diabetes, and high cholesterol. The study highlights the need for increased awareness among healthcare professionals and improved health management strategies for cancer survivors.
A new study uses artificial intelligence to predict bone fractures in cancer patients by creating a digital twin of the vertebra. The AI-assisted framework, ReconGAN, simulates how tumors affect the spine and predicts fracture risks, offering medical experts better treatment strategies and patient decisions.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
Scientists have discovered anticancer substances in kudzu roots and soy molasses that can fight cancer, especially when chemotherapy or surgery are dangerous. The isoflavonoids in these plant extracts mimic human estrogen and bind to free radicals, leading to various diseases including cancer formation.
Paczesny will explore biomarkers and a new type of immune cell to identify and regulate acute lung injury after BMT. She aims to improve understanding of signaling mechanisms in lung injury after BMT, particularly as they relate to idiopathic pneumonia syndrome.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Sophie Paczesny's research aims to validate biomarker panels that help doctors predict chronic GVHD risk and adjust immune suppression treatments accordingly. The study uses machine learning algorithms to analyze stored plasma and blood cell samples from over 1,300 BMT recipients.
Survival rates for adult patients with relapsed acute lymphoblastic leukemia (ALL) after hematopoietic cell transplantation have increased significantly over the past two decades. The two-year overall survival rate rose from 27.8% in 2000-2004 to 54.8% in 2015-2019, despite a significant increase in patient age at relapse.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
Researchers discovered that acute myeloid leukemia (AML) depends on a transporter to bring in inositol, a sugar required for cells to survive. By blocking this transporter, cancer cells would starve without inositol. This method leaves normal cells unharmed as they can produce their own inositol.
Researchers at Duke University and UC Irvine identify Kenpaullone, a cancer drug, as an effective analgesic for chronic and challenging-to-treat pain. The compound enhances Kcc2 gene expression, which resets maladaptive genetic switches in neurons, leading to pain signal silencing.
Researchers at University of Virginia Health System have discovered a new treatment target for osteoporosis and bone loss from rheumatoid arthritis. A cellular protein called ELMO1 promotes the activity of osteoclasts, which break down bone, leading to excessive bone degradation.
Researchers found that remnant cholesterol levels above 24 micrograms per deciliter were associated with a 40-50% higher risk of major heart disease or stroke. The study suggests using remnant cholesterol as an additional metric for predicting cardiovascular disease and stroke risk, in addition to LDL cholesterol levels.
Researchers at Rice and Baylor are expanding their efforts to halt bone cancer metastasis using a molecule targeting osteoporosis and HER2 protein. Their goal is to improve drug concentration at tumor sites, inhibit secondary metastasis, and explore the therapeutic effect mechanism.
Researchers identified a protein called neurexin-1 in cancer stem-like cells that are resistant to chemotherapy and responsible for recurrence. Patients with higher levels of this protein have poorer outcomes and lower survival rates.
Researchers identified glypican-1 protein that prevents cancer cells from spreading to bone, reducing aggressiveness. The study provides a potential new target for future treatments and supports previous findings suggesting the protein's role in preventing tumor growth.
A recent study suggests that cancer prevalence in medieval Britain may be around 9-14%, significantly higher than the previous estimate of less than 1%. The research used x-rays and CT scans to analyze skeletal remains from six medieval cemeteries, revealing signs of malignancy in five individuals.
A landmark study by researchers from the SWOG Cancer Research Network has found that 2.8 percent of cancer patients develop osteonecrosis of the jaw within three years of starting zoledronic acid treatment. The study, which followed 3,491 patients over three years, also identified risk factors and impact on quality of life.
Researchers found that too little sugar can lead to more bone-eating cells in people with bone marrow cancer. A special type of sugar water was shown to reduce perforations and cancer growth in mice with bone marrow cancer. Further animal experiments are needed to develop a treatment for humans.
A clinical trial led by Fred Hutchinson Cancer Center found the iCanQuit app to be nearly 1.5 times more effective in helping adult smokers quit after 12 months compared to the National Cancer Institute's QuitGuide app. The study suggests that for every 100,000 smokers reached with iCanQuit, 28,000 would quit smoking.
WSU researchers have developed a new approach using soy-based compounds to reduce bone cancer cell viability and promote healthy bone cell growth. The slow release of these compounds from 3D-printed scaffolds showed promise in reducing inflammation and improving overall recovery.
Researchers at Royal Ontario Museum and McMaster University diagnosed osteosarcoma, an aggressive bone cancer, in a Centrosaurus apertus dinosaur fossil. The diagnosis was made possible by advanced imaging techniques and microscopic analysis of the fossil bone.
Researchers at MU successfully treated bone cancer in dogs with a vaccine that stimulates the immune system against abnormal proteins specific to the patient's tumor. The treatment outperformed chemotherapy, resulting in over 400 days of cancer survival for dogs compared to about 270 days for those receiving traditional chemotherapy.
Researchers identify key genes driving bone cancer spread to lungs and develop a gene therapy approach that stops the spread in mice. The breakthrough could lead to 'kinder' treatments for children with bone cancer, saving lives.
A new IOF review emphasizes the importance of long-term follow-up to maintain bone health in childhood cancer survivors. The study highlights the need for careful monitoring and management to prevent premature onset of low bone mineral density and improve fracture risk.
A study published in JNCI Cancer Spectrum found that diets high in soy foods are associated with a decreased risk of osteoporotic bone fractures in pre-menopausal breast cancer survivors. Soy intake was linked to a 77% reduced risk of fractures, particularly among younger women.
A case study documents a highly malignant bone tumor in a 240-million-year-old stem-turtle from the Triassic period. The appearance of the tumor conforms with present-day periosteal osteosarcoma in humans, providing valuable insights into the history of cancer in tetrapod evolution.
Scientists discovered complex genetic rearrangements in Ewing Sarcomas that can take years to form, potentially leading to earlier diagnosis and treatment. These findings suggest that some childhood cancers may be detectable before they reveal themselves as disease.
Scientists at MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer in mice, enabling better understanding and treatment of bone metastasis. The model reveals how cancer cells interact with bone and bone resident cells over time, providing insights into the disease's progression.
Acute myeloid leukemia (AML) has a poor five-year survival rate of less than 20%. Researchers at the National University of Singapore identified a novel molecular pathway involving circadian clock gene SHARP1, which causes AML growth. Removing or reducing SHARP1 levels can stop leukemic cell growth.
A new study from St. Jude Children's Research Hospital and the American University of Beirut Medical Center demonstrates effective childhood cancer treatment in a refugee setting. The institution adapted its services to prioritize curable cases, showcasing a viable model for crisis response.
A recent study found a genetic relationship between hCMV reactivation and GVHD, suggesting personalized antiviral treatments could reduce complications in stem cell transplant patients. Researchers sequenced the DNA of 77 donors and recipients, identifying similarities between hCMV peptides and those expressed in GVHD-affected tissue.
Researchers are developing customized 3D implants that can be printed in real-time during tumor surgery, allowing for more precise treatment of bone cancer. This innovative technology has the potential to improve patient outcomes and expand surgical options.
A genetic study has identified a subset of osteosarcoma patients who may respond to IGF1R inhibitors based on their genetic profile. The study found that 10% of patients with a specific mutation in growth factor signalling genes could benefit from existing drugs.
Archaeologists discover a 14-16 year old with bone cancer from the pre-Colombian settlement Cerro Brujo, Panama, dated around 1300 AD. The individual was buried in a fetal position with clay pots and a shell trumpet, indicating a ritual burial.
Researchers have identified two sarcoma subtypes, leiomyosarcoma and pleomorphic, as likely susceptible to immunotherapy. The study analyzed 81 patient samples, revealing patterns of immune response that suggest these subtypes can be targeted with checkpoint inhibitors.
A recent study found that cord blood transplants may be the best option for high-risk leukemia patients, offering a lower risk of relapse compared to traditional transplants. Researchers at Fred Hutchinson Cancer Center discovered that these patients have better outcomes against leukemia and related bone marrow disorders.
A team of researchers discovered the oldest evidence for cancer and bony tumors in human fossils, dating back 1.7 million years. The findings push back the origins of these diseases from recent times to deep prehistory.
Researchers at University of Illinois successfully tested nanoparticle drug delivery in dogs with naturally occurring bone cancers, which are similar to human bone tumors. The study demonstrated anti-cancer activity and tolerance to high doses without toxicity in the dogs.
Researchers analyzed data from Washington State hospital database and found no difference in cancer rates between patients who received rhBMP and those who did not. The study's findings suggest that additional follow-up is needed to rule out any longer-term increase in cancer risk.
Researchers at Kyoto University's Yamada lab created a mouse model to study the EWS-FLI1 gene's role in bone cancer. The model revealed that other mutations are necessary for cancer development and that correcting osteogenic cell differentiation could prevent bone cancers.
According to a Norwegian study of male cancer patients diagnosed under the age of 25, many male cancer patients have problems reproducing. The researchers found that male cancer survivors are three times as likely to turn to assisted fertilization to have children as males with no cancer diagnosis.
A new antibody treatment has shown promise in blocking the process of bone degradation caused by osteosarcoma, a rare type of bone cancer. The treatment reduced bone degradation by up to 80% in a cancer mouse model, offering hope for reducing amputations among young patients.
A new study analyzed 527 patients who underwent spinal fusion surgery using recombinant human bone morphogenetic protein (rhBMP) and found high rates of successful fusion and low rates of complications. The study found no significantly increased risk of cancer, contradicting previous concerns.
Researchers at Rice University have developed a way to mimic the conditions under which cancer tumors grow in bones, enabling more accurate testing of cancer-fighting drugs. The study found that bone tumors exposed to normal forces express more of a protein called IGF-1 than detected in static cultures.
A clinical trial at University of Colorado Anschutz Medical Campus demonstrates an intervention that successfully reduces caregiver stress in cancer patients treated with stem cell transplantation. The study shows significant lower stress levels and improved quality of life for caregivers.
A new stem cell disease model reveals how a protein known to prevent tumor growth in most cases may drive bone cancer when genetic changes cause its overproduction. The study focused on rare genetic disease Li-Fraumeni Syndrome, which increases the risk of many cancers, including osteosarcoma.
Researchers found that bisphosphonate users were half as likely to develop endometrial cancer, suggesting a potential preventive effect. The study suggests that women taking bone-strengthening medications with increased endometrial cancer risk may benefit from nitrogen-form bisphosphonates.
A new study identifies Ewing sarcoma-associated transcript 1 (EWSAT1) as a critical target of the EWS-FLI1 fusion protein, contributing to cancer cell growth and repression of key genes. This finding supports the notion that long noncoding RNAs can drive cancer development and highlights an important mediator in Ewing Sarcoma.
Researchers redesigned a molecule to control immune cell activity, changing its target and altering the effects of its signal. This new approach may let scientists selectively block the bad signals that cause or contribute to disease, enhancing good signals that defend against cancer and infections.
A new mouse model reveals that high levels of Notch1 can transform osteoblasts into cancerous cells, leading to osteogenic sarcoma. This study supports the hypothesis that Notch activating mutations can act as a common triggering mechanism in bone cancer.
Research identifies RAS oncogene involvement in DS-ALL cases, highlighting genetic insights into leukemia risk in children with Down syndrome. Geneticists sequenced exomes of affected individuals, shedding light on disease characteristics.
Certain cancers have a characteristic age at which they occur, and their incidence decreases beyond that age. This 'developmental origin of disease hypothesis' suggests many cancers originate early in life, possibly before birth.
Researchers developed a drug-delivery system that targets bone cancer cells, reducing growth and prolonging survival in mice. The nanoparticles also stimulated healthy bone tissue growth, increasing strength and volume.